Trial design & development strategy
Development choices tested against the questions the evidence will have to answer.
Shortlist it, send it over — we come back with the shape we'd actually recommend.
What trial design & development strategy actually is.
Strategic input into the choices that determine whether a trial answers the questions decision-makers will actually ask: endpoints, comparators, populations, subgroups and the sequencing of studies across the programme.
We work alongside your clinical, regulatory and biostatistics teams. Protocol authorship, statistical analysis planning and trial operations remain with them or with a CRO; our role is to test the design against downstream regulatory, HTA and payer expectations while those choices are still open.
- Design review against regulatory, HTA and payer expectations
- Endpoint, comparator and population options with trade-offs
- Precedent analysis from comparable programmes and prior critique
- Downstream evidence risks named early, with mitigations
- Working session with clinical, regulatory and access
Add the pieces you'd want and we'll build a shortlist you can review, reorder and send over. No pricing wall, no commitment — we come back with what we'd actually recommend, including anything you don't need.
Think this belongs in your scope?
Add it alongside anything else that fits, then send the shortlist over. We'll reply with the shape we'd recommend — sequence included, and the parts we think you can skip.
Build what comes next.
Whether you need growth, answers or capability, VISFO helps you move earlier and faster.